Cargando…

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)

Background. FGFR1/2/3 fusions have been reported infrequently in aNSCLC, including as a rare, acquired resistance mechanism following treatment with EGFR TKIs. Data regarding their prevalence and therapeutic implications are limited. Methods. The Guardant Health (GH) electronic database (ED) was eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Raphael, Ari, Dudnik, Elizabeth, Hershkovitz, Dov, Jain, Suyog, Olsen, Steve, Soussan-Gutman, Lior, Ben-Shitrit, Taly, Dvir, Addie, Nechushtan, Hovav, Peled, Nir, Onn, Amir, Agbarya, Abed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102087/
https://www.ncbi.nlm.nih.gov/pubmed/35566609
http://dx.doi.org/10.3390/jcm11092475
_version_ 1784707246500872192
author Raphael, Ari
Dudnik, Elizabeth
Hershkovitz, Dov
Jain, Suyog
Olsen, Steve
Soussan-Gutman, Lior
Ben-Shitrit, Taly
Dvir, Addie
Nechushtan, Hovav
Peled, Nir
Onn, Amir
Agbarya, Abed
author_facet Raphael, Ari
Dudnik, Elizabeth
Hershkovitz, Dov
Jain, Suyog
Olsen, Steve
Soussan-Gutman, Lior
Ben-Shitrit, Taly
Dvir, Addie
Nechushtan, Hovav
Peled, Nir
Onn, Amir
Agbarya, Abed
author_sort Raphael, Ari
collection PubMed
description Background. FGFR1/2/3 fusions have been reported infrequently in aNSCLC, including as a rare, acquired resistance mechanism following treatment with EGFR TKIs. Data regarding their prevalence and therapeutic implications are limited. Methods. The Guardant Health (GH) electronic database (ED) was evaluated for cases of aNSCLC and FGFR2/3 fusions; FGFR2/3 fusion prevalence with and without a co-existing EGFR mutation was assessed. The ED of Tel-Aviv Sourasky Medical Center (TASMC, June 2020–June 2021) was evaluated for cases of aNSCLC and de novo FGFR1/2/3 fusions. Patients with EGFR mutant aNSCLC progressing on EGFR TKIs and developing an FGFR1/2/3 fusion were selected from the ED of Davidoff Cancer Center (DCC) and Oncology Department, Bnei-Zion hospital (BZ) (April 2014–April 2021). Clinicopathological characteristics, systemic therapies, and outcomes were assessed. Results. In the GH ED (n = 57,445), the prevalence of FGFR2 and FGFR3 fusions were 0.02% and 0.26%, respectively. FGFR3-TACC3 fusion predominated (91.5%). In 23.8% of cases, FGFR2/3 fusions co-existed with EGFR sensitizing mutations (exon 19 del, 64.1%; L858R, 33.3%, L861Q, 2.6%). Among samples with concurrent FGFR fusions and EGFR sensitizing mutations, 41.0% also included EGFR resistant mutations. In TASMC (n = 161), 1 case of de novo FGFR3-TACC3 fusion was detected (prevalence, 0.62%). Of three patients from DCC and BZ with FGFR3-TACC3 fusions following progression on EGFR TKIs, two received EGFR TKI plus erdafitinib, an FGFR TKI, with clinical benefit duration of 13.0 and 6.0 months, respectively. Conclusions. Over 23% of FGFR2/3 fusions in aNSCLC may be associated with acquired resistance following treatment with EGFR TKIs. In this clinical scenario, a combination of EGFR TKIs and FGFR TKIs represents a promising treatment strategy.
format Online
Article
Text
id pubmed-9102087
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91020872022-05-14 FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC) Raphael, Ari Dudnik, Elizabeth Hershkovitz, Dov Jain, Suyog Olsen, Steve Soussan-Gutman, Lior Ben-Shitrit, Taly Dvir, Addie Nechushtan, Hovav Peled, Nir Onn, Amir Agbarya, Abed J Clin Med Article Background. FGFR1/2/3 fusions have been reported infrequently in aNSCLC, including as a rare, acquired resistance mechanism following treatment with EGFR TKIs. Data regarding their prevalence and therapeutic implications are limited. Methods. The Guardant Health (GH) electronic database (ED) was evaluated for cases of aNSCLC and FGFR2/3 fusions; FGFR2/3 fusion prevalence with and without a co-existing EGFR mutation was assessed. The ED of Tel-Aviv Sourasky Medical Center (TASMC, June 2020–June 2021) was evaluated for cases of aNSCLC and de novo FGFR1/2/3 fusions. Patients with EGFR mutant aNSCLC progressing on EGFR TKIs and developing an FGFR1/2/3 fusion were selected from the ED of Davidoff Cancer Center (DCC) and Oncology Department, Bnei-Zion hospital (BZ) (April 2014–April 2021). Clinicopathological characteristics, systemic therapies, and outcomes were assessed. Results. In the GH ED (n = 57,445), the prevalence of FGFR2 and FGFR3 fusions were 0.02% and 0.26%, respectively. FGFR3-TACC3 fusion predominated (91.5%). In 23.8% of cases, FGFR2/3 fusions co-existed with EGFR sensitizing mutations (exon 19 del, 64.1%; L858R, 33.3%, L861Q, 2.6%). Among samples with concurrent FGFR fusions and EGFR sensitizing mutations, 41.0% also included EGFR resistant mutations. In TASMC (n = 161), 1 case of de novo FGFR3-TACC3 fusion was detected (prevalence, 0.62%). Of three patients from DCC and BZ with FGFR3-TACC3 fusions following progression on EGFR TKIs, two received EGFR TKI plus erdafitinib, an FGFR TKI, with clinical benefit duration of 13.0 and 6.0 months, respectively. Conclusions. Over 23% of FGFR2/3 fusions in aNSCLC may be associated with acquired resistance following treatment with EGFR TKIs. In this clinical scenario, a combination of EGFR TKIs and FGFR TKIs represents a promising treatment strategy. MDPI 2022-04-28 /pmc/articles/PMC9102087/ /pubmed/35566609 http://dx.doi.org/10.3390/jcm11092475 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Raphael, Ari
Dudnik, Elizabeth
Hershkovitz, Dov
Jain, Suyog
Olsen, Steve
Soussan-Gutman, Lior
Ben-Shitrit, Taly
Dvir, Addie
Nechushtan, Hovav
Peled, Nir
Onn, Amir
Agbarya, Abed
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
title FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
title_full FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
title_fullStr FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
title_full_unstemmed FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
title_short FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
title_sort fgfr fusions as an acquired resistance mechanism following treatment with epidermal growth factor receptor tyrosine kinase inhibitors (egfr tkis) and a suggested novel target in advanced non-small cell lung cancer (ansclc)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102087/
https://www.ncbi.nlm.nih.gov/pubmed/35566609
http://dx.doi.org/10.3390/jcm11092475
work_keys_str_mv AT raphaelari fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT dudnikelizabeth fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT hershkovitzdov fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT jainsuyog fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT olsensteve fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT soussangutmanlior fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT benshitrittaly fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT dviraddie fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT nechushtanhovav fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT pelednir fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT onnamir fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT agbaryaabed fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc
AT fgfrfusionsasanacquiredresistancemechanismfollowingtreatmentwithepidermalgrowthfactorreceptortyrosinekinaseinhibitorsegfrtkisandasuggestednoveltargetinadvancednonsmallcelllungcanceransclc